ST. DAVID'S, Bermuda, March 14 /PRNewswire/ --

It is with a profound sense of loss that Warner Chilcott Limited (Nasdaq: WCRX) reports today that Mr. James G. Andress, a director of the Company, died on Tuesday, March 11, 2008.

Roger Boissonneault, Chief Executive Officer, President and Director of Warner Chilcott Limited, issued the following statement:

"We report the loss of Jim Andress with great sadness. Jim was instrumental in the development of this Company. His thoughtful guidance and counsel will be sorely missed. Our deepest sympathies go out to Jim's family."

Recently, mathematician Daniel J. Madden and retired physicist Lee W. Jacobi found solutions to a puzzle that has been around for centuries - an infinite number of solutions for a puzzle known as 'Euler’s Equation of degree four.'

The equation is part of a branch of mathematics called number theory. Number theory deals with the properties of numbers and the way they relate to each other. It is filled with problems that can be likened to numerical puzzles.

“It’s like a puzzle: can you find four fourth powers that add up to another fourth power" Trying to answer that question is difficult because it is highly unlikely that someone would sit down and accidentally stumble upon something like that,” said Madden, an associate professor of mathematics at The University of Arizona in Tucson.

LONDON, March 14 /PRNewswire/ -- creativebrief, the first and only global online service connecting up the marketing and creative industries is delighted to announce the launch of its third edition website.

After 5 years of experience developing the world's only interactive database for the marketing services industry, creativebrief took the learning, and comments from clients and agencies alike and spent 9 months developing the new v3 site.

Designed to take advantage of the very latest in navigation, delivery and functionality the site is developed in open source and is, for the first time, a flexible platform able to adapt quickly to clients' changing needs.

WICHITA, Kansas, March 14 /PRNewswire/ --

Spirit AeroSystems, Inc. (NYSE: SPR) announced Rolls-Royce as the customer for one of its previously awarded business jet contracts. Spirit has been selected to design and build the nacelle, thrust reverser and engine build up components for the Rolls-Royce BR725 engine; a contract worth in excess of US$600 million. Spirit will also support the aforementioned products in the Rolls-Royce Corporate Care Program throughout the life of the airplane. The BR725 is the selected engine for Gulfstream's recently-announced G650 business jet.

LONDON, March 14 /PRNewswire/ --

- Launches DTH Services Across Europe, North Africa & Middle East

- ARY & B4U Join Soft Launch

Pyramid Saimira Entertainment Ltd, a wholly-owned subsidiary of Pyramid Saimira Theatre Ltd (NSE: PSTL; BSE: 532791), has entered into a strategic partnership with UK-based Spize TV, a Direct-to-home platform. Through the partnership, Pyramid Saimira Entertainment Ltd will facilitate content agglomeration and new channels services, on Spize TV. An associate company of the Pyramid Saimira Group had earlier picked up an equity stake in Spize TV.

There are a number of interconnected factors that lead to the success or failure of any business so it is usually considered an impossible task to predict whether a company will sink or swim numerically but researchers in Taiwan using the principles of evolutionary biology say they have devised an approach to spotting when a company is likely to fail.

Ping-Chen Lin of the National Kaohsiung University of Applied Sciences in Kaohsiung and Jiah-Shing Chen of the National Central University, Jhongli, in Taiwan, also explain how their metric of the financial status of any company can be of interest not only to its owners and employees but to a range of creditors, stockholders, banks, and individual investors.

LONDON, March 14 /PRNewswire/ -- An ongoing strike involving maintenance craft workers at Doncaster and Bassetlaw Hospitals NHS Foundation Trust is set to build and spread.

24 Unite maintenance members are in dispute over the trust's failure to honour a national pay agreement and they are building up their action, striking again today (Friday 14th March) and twice again next week (Monday 17th and Thursday 19th March).

They may also be joined by Unison maintenance workers who are now balloting for strike action.

The Trust is refusing to implement a recruitment and retention premia which is part of a national pay agreement agreed under Agenda for Change. The premia amounts to around GBP3,000 per year.

LONDON, March 14 /PRNewswire/ --

- Photo Opportunity: Tuesday 18th March 2008 - 12 Noon Outside Downing Street

Unite members will next Tuesday (18th March 2008) be handing in a petition to Downing Street as part of the campaign to keep vital services open at Bridlington Hospital.

Activists will be handing a petition with over 37,000 signatures to Downing Street and meeting MPs, as part of the campaign opposing the closure of the Cardiac Monitoring Unit and two acute medical wards at the hospital. Unite has consistently said the trust's plans will put patient's lives at risk.

Writing in the Journal of the American Medical Association, a medical team from the University of Leicester say they have established a predictor for pregnant women who may have miscarriages and those who won’t.

The researchers measured the levels of a naturally occurring ‘cannabis’ (an endocannabinoid) known as anandamide in women who presented with a threatened miscarriage (bleeding in early pregnancy with a viable baby) and found that those who at the time of the test had significantly higher levels of anandamide subsequently miscarried.

STOCKHOLM, Sweden, March 14 /PRNewswire/ -- Diamyd Medical AB (http://www.omxgroup.com, ticker: DIAM B; http://www.otcqx.com, ticker DMYDY). The FDA has given Diamyd Medical permission to start a Phase III clinical study in type 1 diabetes patients in the US with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients", says Professor Jerry Palmer, University of Washington in Seattle, USA, who will be the Lead Investigator for the US study.